John Paulson’s Q3 2025 13F portfolio surged to ~$2.97B, concentrated in just 10 securities, with Madrigal Pharma (MDGL) as ...
One of the most critical fallacies of portfolio benchmarking is the disparity between compound and variable rates of return. The importance of buybacks cannot be overlooked. Comparing your performance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback